Asia PR News

SINGAPORE and IRVINE, Calif., Oct. 27 /PRNewswire-AsiaNet/ –

PrimeGen Biotech, LLC, a 3 year old privately-held stem cell engineering
firm, announced today that it will present results of its research on the
therapeutic reprogramming of murine germ-line stem cells at the Keystone
Symposium on Stem Cells, Senescence and Cancer, currently being held in
Singapore. The poster presentation will occur on Friday, October 28 from 3:30
to 5:30 PM at the conference.

The company’s data demonstrate that post-natal murine germ-line stem cells,
which normally differentiate only into sperm and eggs, can be reprogrammed to
be pluripotent. These reprogrammed germ-line stem cells, which the company has
termed PrimeCell(TM), express embryonic stem cell (ESC)-specific markers and
were successfully directed to differentiate into multiple tissue types,
including cardiac muscle and neural cell types. The data also demonstrate that
therapeutically reprogrammed germ-line stem cells injected into mouse
blastocysts give rise to all three germ layers in the murine embryo,
substantiating the finding that the cells are pluripotent.

Unlike existing embryonic stem cell lines or adult stem cell lines from any
other known source, germ-line stem cells possess a uniquely conserved genome.
These cells have been evolutionarily conserved to maintain the highest level of
genetic integrity, which enables successful propagation of species.

"Our work with murine spermatogonial stem cells demonstrates the potential
to apply our therapeutic reprogramming approach to human-derived germ-line
cells for the development of regenerative therapies," said Francisco Silva,
Executive Vice President of R&D at PrimeGen. "Because of PrimeCell’s unique
genetic integrity, conditioned pluripotentiality and the fact that it is
derived from a post-natal source, we believe it will be the most
therapeutically valuable stem cell available to treat a wide range of
degenerative disorders."

About Keystone Symposia
Keystone Symposia, a non-profit organization, has a 35-year history of
organizing high quality scientific conferences to connect the scientific
community and accelerate discoveries that benefit society.

About PrimeGen Biotech, LLC
Founded in 2002, PrimeGen Biotech, LLC is a privately-held stem cell
engineering firm dedicated to optimizing the therapeutic potential of adult
stem cells. The company’s premier platform, PrimeCell(TM), is based on the
therapeutic reprogramming of germ-line stem cells to yield a pristine,
pluripotent adult stem cell. For more information, visit
www.primegenbiotech.com

CONTACT:
Virginia Amann or Jennifer MacArthur
Atkins + Associates
for PrimeGen Biotech
608-274-6046 or 858-527-3497
vamann@irpr.com
jmacarthur@irpr.com

SOURCE: PrimeGen Biotech, LLC

CONTACT: Virginia Amann,
+1-608-274-6046,
vamann@irpr.com, or

Jennifer MacArthur,
+1-858-527-3497,
jmacarthur@irpr.com,

both of Atkins + Associates,
for PrimeGen Biotech, LLC

Web site: http://www.primegenbiotech.com